NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: V
Post# of 111
(Total Views: 248)
Posted On: 03/21/2019 4:27:08 PM
NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) Starts Australian Observational Trial
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) today announced that it will begin an observational study on the use of cannabinoids as therapy for chronic pain. A group of well-known pain specialists will lead the study, taking place in Melbourne, Australia, which expects to provide long-term (24 month) data in order to evaluate the efficacy of medical cannabis in treating pain and further support development of VIVO’s portfolio of medical cannabis products. VIVO is funding the effort in the form of a research grant to its partner in the study, Australian Medical Cannabis Service (“AMCS”). “Driven by unmet clinical needs, medical cannabis products and treatment plans continue to gain momentum in Australia,” VIVO Chief Executive Officer Barry Fishman said in the news release. “The Study will help to inform VIVO’s product development through data gathered from both patients and physicians. This access to primary data is expected to continue to ensure our products address the specific health and wellness needs of our clients and customers, something that we believe provides distinct advantage. We remain committed to ensuring Australians have access to our medical cannabis, and to our efforts to change the way people view cannabis.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) today announced that it will begin an observational study on the use of cannabinoids as therapy for chronic pain. A group of well-known pain specialists will lead the study, taking place in Melbourne, Australia, which expects to provide long-term (24 month) data in order to evaluate the efficacy of medical cannabis in treating pain and further support development of VIVO’s portfolio of medical cannabis products. VIVO is funding the effort in the form of a research grant to its partner in the study, Australian Medical Cannabis Service (“AMCS”). “Driven by unmet clinical needs, medical cannabis products and treatment plans continue to gain momentum in Australia,” VIVO Chief Executive Officer Barry Fishman said in the news release. “The Study will help to inform VIVO’s product development through data gathered from both patients and physicians. This access to primary data is expected to continue to ensure our products address the specific health and wellness needs of our clients and customers, something that we believe provides distinct advantage. We remain committed to ensuring Australians have access to our medical cannabis, and to our efforts to change the way people view cannabis.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VIVO Cannabis Inc. (VVCIF) Stock Research Links
Scroll down for more posts ▼